GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Precipio Inc (NAS:PRPO) » Definitions » Debt-to-EBITDA

Precipio (Precipio) Debt-to-EBITDA : 0.21 (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Precipio Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Precipio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.59 Mil. Precipio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.53 Mil. Precipio's annualized EBITDA for the quarter that ended in Dec. 2023 was $5.20 Mil. Precipio's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.21.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Precipio's Debt-to-EBITDA or its related term are showing as below:

PRPO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.39   Med: -0.45   Max: -0.13
Current: -0.26

During the past 13 years, the highest Debt-to-EBITDA Ratio of Precipio was -0.13. The lowest was -3.39. And the median was -0.45.

PRPO's Debt-to-EBITDA is ranked worse than
100% of 105 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.96 vs PRPO: -0.26

Precipio Debt-to-EBITDA Historical Data

The historical data trend for Precipio's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Precipio Debt-to-EBITDA Chart

Precipio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.17 -0.17 -0.20 -0.13 -0.26

Precipio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.18 -0.11 -0.14 -0.31 0.21

Competitive Comparison of Precipio's Debt-to-EBITDA

For the Diagnostics & Research subindustry, Precipio's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Precipio's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Precipio's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Precipio's Debt-to-EBITDA falls into.



Precipio Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Precipio's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.585 + 0.531) / -4.318
=-0.26

Precipio's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.585 + 0.531) / 5.204
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Precipio  (NAS:PRPO) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Precipio Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Precipio's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Precipio (Precipio) Business Description

Traded in Other Exchanges
N/A
Address
4 Science Park, New Haven, CT, USA, 06511
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings.
Executives
Richard A Sandberg director 330 NEVEDA STREET, NEWTON MA 02460-1458
Ahmed Zaki Sabet officer: Chief Operations Officer 33 ANDYS DR, EAST HAVEN CT 06512
Ilan Danieli director, officer: Chief Executive Officer 14707 CALIFORNIA STREET, SUITE 5, OMAHA NE 68154
Matthew Gage officer: Chief Financial Officer 56 STAGECOACH CIRCLE, MILFORD CT 06460
David Seth Cohen director, 10 percent owner C/O STANDARD OIL, 299 BISHOP AVENUE, BRIDGEPORT CT 06610
Ronald Asbury Andrews director 5791 VAN ALLEN WAY, CARLSBAD CA 92008
Randal J Kirk 10 percent owner 1881 GROVE AVENUE, RADFORD VA 24141
Kathleen Laporte director
Robert Patzig director THE GOVERNOR TYLER, 1881 GROVE AVENUE, RADFORD VA 24141
Michael A Luther director 21 CORPORATE CIRCLE, ALBANY NY 12203
Jeffrey Cossman director C/O PRECIPIO INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Samuel D Riccitelli director 2850 FRONTIER DR., WARSAW IN 46582
Carl Iberger officer: Chief Financial Officer C/O PRECIPIO, INC., 12325 EMMET STREET, OMAHA NE 68164
Douglas Fisher director 587 PATROL RD, WOODSIDE CA 94062
Mark Rimer director, 10 percent owner C/O PRECIPIO, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511